With 1.07 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.05 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $2.92 whereas the lowest price it dropped to was $2.7. The 52-week range on SVRA shows that it touched its highest point at $5.34 and its lowest point at $2.26 during that stretch. It currently has a 1-year price target of $9.44. Beta for the stock currently stands at 0.52.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SVRA was up-trending over the past week, with a rise of 3.25%, but this was up by 23.28% over a month. Three-month performance dropped to -9.21% while six-month performance fell -32.55%. The stock lost -42.57% in the past year, while it has lost -6.84% so far this year. A look at the trailing 12-month EPS for SVRA yields -0.48 with Next year EPS estimates of -0.41. For the next quarter, that number is -0.13. This implies an EPS growth rate of -9.90% for this year and 22.91% for next year. EPS is expected to grow by 41.72% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of 24.35%.
Float and Shares Shorts:
At present, 172.42 million SVRA shares are outstanding with a float of 84.90 million shares on hand for trading. On 2025-03-14, short shares totaled 17.33 million, which was 1010.0000000000001 higher than short shares on 1739491200. In addition to Mr. Matthew Pauls J.D., M.B.A. as the firm’s Chairman & CEO, Mr. David L. Lowrance CPA serves as its CFO, Chief Administrative Officer & Secretary.
Institutional Ownership:
Through their ownership of 0.97248 of SVRA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-12-31, SVRA reported revenue of $0.0 and operating income of -$31174000.0. The EBITDA in the recently reported quarter was -$31359000.0 and diluted EPS was $nan.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SVRA since 6 analysts follow the stock currently. There are 6 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SVRA analysts setting a high price target of 16.0 and a low target of 3.0, the average target price over the next 12 months is 9.4375. Based on these targets, SVRA could surge 459.44% to reach the target high and rise by 4.9% to reach the target low. Reaching the average price target will result in a growth of 229.98% from current levels.
EPS: Estimates vs Actual
It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.451 being high and -$0.4715 being low. For SVRA, this leads to a yearly average estimate of -$0.46125.
